NLRP3 and COVID-19: A recent animal study showed that remdesivir may be nephroprotective in COVID-19 via effective inhibition of inflammatory immune responses, which specifically repress NLRP3 inflammasome activation in lipopolysaccharide (LPS)-activated macrophages in mice models [32].